Malignant melanoma within the gastrointestinal tract is an uncommon neoplasm that is usually metastatic in origin, with primary melanomas being relatively uncommon. Embryologically melanocytes normally exist in the esophagus, stomach, small bowel, and anorectum and this theory supports the primary melanoma of the gastrointestinal tract that has been confirmed for lesions occurring through several published reports. However, most patients with brain metastases from malignant melanoma are diagnosed after treatment for known extracranial metastases and have poor outcomes. Our case is unique in that we discuss an unusual case of 69-year-old female patient presented with unsteady gait as the first symptom of disease and where the presumed primary lesion later was found in the terminal ileum on colonoscopy. Treatment consisted of surgical removal of the terminal ileal lesion with chemotherapy, whole-brain radiotherapy, and cyberknife radiosurgical procedure. Patient was in remission for more than 14 months and later succumbed to disease. Despite the advances in therapeutic options, prognosis for patients with melanoma brain metastases remains poor with a median survival time of six months after diagnosis. 1. Introduction Next to lung cancer, malignant melanoma is the most frequent cause of brain metastasis. In a large series from the Metropolitan Detroit Cancer, the cumulative incidence of melanoma brain metastasis is <10% and usually develop late in the course of the disease [1, 2]. Metastatic spread of tumor cells detached from melanoma into the central nervous system (CNS) occurs haematogenically since lymphatic drainage is absent in the brain. The blood-brain barrier is usually intact in metastases that are smaller than 0.25？mm in diameter because melanoma micrometastases are common in the brain and patients can harbor numerous metastases in the brain without any neurological deficits [3, 4]. Furthermore, while melanoma can present in the brain as the first site of metastasis, it is more common for brain metastasis to present later in the course of disease, most often acting as a harbinger of terminal disease. The course of disease is typically characterized by rapid extra cranial progression and short overall survival time despite various local and systemic treatment approaches. While surgery and radiotherapy interventions can prolong the disease-free interval when solitary, large metastases in the brain are found early in the course of melanoma metastasis; these treatments provide only short-term, but nevertheless important, palliation in patients with
References
[1]
J. S. Barnholtz-Sloan, A. E. Sloan, F. G. Davis, F. D. Vigneau, P. Lai, and R. E. Sawaya, “Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System,” Journal of Clinical Oncology, vol. 22, no. 14, pp. 2865–2872, 2004.
[2]
L. J. Schouten, J. Rutten, H. A. M. Huveneers, and A. Twijnstra, “Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma,” Cancer, vol. 94, no. 10, pp. 2698–2705, 2002.
[3]
L. Holmgren, M. S. O'Reilly, and J. Folkman, “Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression,” Nature Medicine, vol. 1, no. 2, pp. 149–153, 1995.
[4]
A. Y. Bedikian, C. Wei, M. Detry et al., “Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma,” American Journal of Clinical Oncology, vol. 34, no. 6, pp. 603–610, 2011.
[5]
K. M. Fife, M. H. Colman, G. N. Stevens et al., “Determinants of outcome in melanoma patients with cerebral metastases,” Journal of Clinical Oncology, vol. 22, no. 7, pp. 1293–1300, 2004.
[6]
Y. Mishima, “Melanocytic and nevocytic malignant melanomas. Cellular and subcellular differentiation,” Cancer, vol. 20, no. 5, pp. 632–649, 1967.
[7]
A. Amar, J. Jougon, A. Edouard, P. Laban, J. P. Marry, and G. Hillion, “Primary malignant melanoma of the small intestine,” Gastroentérologie Clinique et Biologique, vol. 16, no. 4, pp. 365–367, 1992.
[8]
S. Krüger, F. Noack, C. Bl？chle, and A. C. Feller, “Primary malignant melanoma of the small bowel: a case report and review of the literature,” Tumori, vol. 91, no. 1, pp. 73–76, 2005.
[9]
A. M. Elsayed, M. Albahra, U. C. Nzeako, and L. H. Sobin, “Malignant melanomas in the small intestine: a study of 103 patients,” American Journal of Gastroenterology, vol. 91, no. 5, pp. 1001–1006, 1996.
[10]
G. N. Bender, D. D. T. Maglinte, J. H. McLarney, D. Rex, and F. M. Kelvin, “Malignant melanoma: patterns of metastasis to the small bowel, reliability of imaging studies, and clinical relevance,” American Journal of Gastroenterology, vol. 96, no. 8, pp. 2392–2400, 2001.
[11]
S. H. Poggi, J. F. Madison McNiff, W.-J. P. Hwu, S. Bayar, and R. R. Salem, “Colonic melanoma, primary or regressed primary,” Journal of Clinical Gastroenterology, vol. 30, no. 4, pp. 441–444, 2000.
[12]
F. F. Amersi, A. M. Terando, Y. Goto et al., “Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine,” Clinical Cancer Research, vol. 14, no. 3, pp. 638–645, 2008.
[13]
W. M. Wysocki, A. L. Komorowski, and Z. Darasz, “Gastrointestinal metastases from malignant melanoma: report of a case,” Surgery Today, vol. 34, no. 6, pp. 542–546, 2004.
[14]
N. Brummel, Z. Awad, S. Frazier, J. Liu, and N. Rangnekar, “Perforation of metastatic melanoma to the small bowel with simultaneous gastrointestinal stromal tumor,” World Journal of Gastroenterology, vol. 11, no. 17, pp. 2687–2689, 2005.
[15]
J. M. Klausner, Y. Skornick, and S. Lelcuk, “Acute complications of metastatic melanoma to the gastrointestinal tract,” British Journal of Surgery, vol. 69, no. 4, pp. 195–196, 1982.
[16]
N. Tsilimparis, C. Menenakos, P. Rogalla, C. Braumann, and J. Hartmann, “Malignant melanoma metastasis as a cause of small-bowel perforation,” Onkologie, vol. 32, no. 6, pp. 356–358, 2009.
[17]
T. Mucci, W. Long, A. Witkiewicz, M. J. Mastrangelo, E. L. Rosato, and A. C. Berger, “Metastatic melanoma causing jejunal intussusception,” Journal of Gastrointestinal Surgery, vol. 11, no. 12, pp. 1755–1757, 2007.
[18]
R. Patti, M. Cacciatori, G. Guercio, V. Territo, and G. di Vita, “Intestinal melanoma: a broad spectrum of clinical presentation,” International Journal of Surgery Case Reports, vol. 3, no. 8, pp. 395–398, 2012.
[19]
D. W. Ollila, R. Essner, L. A. Wanek, and D. L. Morton, “Surgical resection for melanoma metastatic to the gastrointestinal tract,” Archives of Surgery, vol. 131, no. 9, pp. 975–980, 1996.
[20]
C. R. Goulart, T. A. Mattei, and R. Ramina, “Cerebral melanoma metastases: a critical review on diagnostic methods and therapeutic options,” ISRN Surgery, vol. 2011, Article ID 276908, 9 pages, 2011.
[21]
J. Gottschalk, S. H. D？pel, J. Schulz, M. Fuchs, and H. Martin, “Significance of immunohistochemistry in neuro-oncology. V. Keratin as a marker for epithelial differentiation of primary and secondary intracranial and intraspinal tumors,” Zentralblatt fur Allgemeine Pathologie und Pathologische Anatomie, vol. 133, no. 2, pp. 133–145, 1987.
[22]
S. Saha, M. Meyer, E. T. Krementz et al., “Prognostic evaluation of intracranial metastasis in malignant melanoma,” Annals of Surgical Oncology, vol. 1, no. 1, pp. 38–44, 1994.
[23]
J. H. Galicich, “Intracranial metastasis of malignant tumors. The classification of parenchymal type, leptomeningeal type and diffuse type and its clinical significance. I. Clinical manifestations,” No Shinkei Geka, vol. 6, no. 1, pp. 29–37, 1978.
[24]
U. Selek, E. L. Chang, S. J. Hassenbusch III et al., “Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases,” International Journal of Radiation Oncology, Biology, Physics, vol. 59, no. 4, pp. 1097–1106, 2004.
[25]
S. L. Wong and D. G. Coit, “Role of surgery in patients with stage IV melanoma,” Current Opinion in Oncology, vol. 16, no. 2, pp. 155–160, 2004.
